Atty. Dkt. No. 047940-0135



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Harvey D. PREISLER

Title:

BINDING-SPECIFIC PEPTIDES, BINDING-SPECIFIC CARRIER

MOLECULES, AND USES THEREOF

Appl. No.:


10/062,587

Filing Date:

1/31/02

Art Unit:

1633



UNDER 37 CFR §1.56

Commissioner for Patents Washington, D.C. 20231

RECEIVED

JUN 1 4 2002

TECH CENTER 1600/2003

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



COPY OF PAPERS ORIGINALLY FILED

Atty. Dkt. No. 047940-0135

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 06-1447. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1447.

Respectfully submitted,

Robert N. Young

Attorney for Applicant

Registration No. 48,412

Date June 5, 2002

FOLEY & LARDNER

Customer Number: 23524

PATENT TRADEMARK OFFICE

Telephone: (

(608) 258-4991

Facsimile:

(608) 258-4258

JUN 1 1 2007 5

COPY OF PAPERS ORIGINALLY FILED

Page 1 of 2

U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. Form PTO-1449 10/062,587 PATENT AND TRADEMARK OFFICE 047940-0135 (MODIFIED) APPLICANT Harvey D. PREISLER INFORMATION DISCLOSURE CITATION GROUP ART UNIT FILING DATE 1633 01/31/2002 (Use several sheets if necessary) **U.S. PATENT DOCUMENTS** FILING DATE SUB-DOCUMENT **EXAMINER** CLASS DATE NAME IF REF **CLASS** INITIAL NUMBER **APPROPRIATE** Renschler et al. 4/30/96 5,512,435 TECH CENTER 1600,2900 FOREIGN PATENT DOCUMENTS TRANSLATION SUB-DOCUMENT CLASS DATE COUNTRY REF **CLASS** NUMBER YE\$ NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) A. Cabibbo et al., "Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hlL-6 D-helix," Gene 167, pp. 41-47, 1995; published by Elsevier Science B.V. M. A. Barry et al., "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries," Nature Medicine 2(3), pp. 299-305, March 1996. R. Pasquallini and E. Ruoslahti, "Organ targeting in vivo using phage display peptide libraries," Nature 380, pp. 364-366, 1996. J. W. Smith and E. Ruoslahti, "Harvesting Molecular Diversity - Biology's New Commodity," Biotech Gen Eng Rev 14, pp. 51-65, April 1997. M. Szardenings et al., "Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1," J Biol Chem 272(44), pp.27943-27948, 1997; published by The American Society for Biochemistry and Molecular Biology, Inc. W. Arap et al., "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," Science 279., pp. 377-380, January 1998. W. Arap et al., "Chemotherapy targeted to tumor vasculature," Curr Opin Oncol 10, pp. 560-565, 1998.



communication to applicant.

COPY OF PAPERS ORIGINALLY FILED

Page 2 of 2

\2	S/
TA TRAS	Samoylova and B. F. Smith, "Elucidation of muscle-binding peptides by phage display screening," Muscle and Nerve, pp. 460-466, April 1999.
V	J. D. Norris et al., "Peptide antagonists of the human estrogen receptor," Science 285, pp. 744-746, July 1999
	V. V. Ivanenkov et al., "Targeted delivery of multivalent phage display vectors into mammalian cells," Biochimica et Biophysica Acta 1448, pp. 463-472, 1999; published by Elsevier Science B.V.
J	E. Koivunen <i>et al.</i> , "Identification of receptor ligands with phage display peptide libraries," <u>J Nucl Med 40</u> , pp. 883-888, 1999.
J	L. Mazzucchelli et al., "Cell-specific peptide binding by human neutrophils," <u>Blood 93</u> , pp. 1738-1748, 1999.
	D. J. Rodi and L. Makowski, "Phage-display technology - finding a needle in a vast molecular haystack," Curr Opin Biotechnol 10(1), pp. 87-93, 1999; published by Elsevier Science B.V.
J	K. C. Brown, "New approaches for cell-specific targeting: Identification of cell-selective peptides from combinatorial libraries," <u>Curr Opin Chem Biol 4</u> , pp. 16-21, 2000; published by Elsevier Science B.V.
J	F. D. Hong and G. L. Clayman, "Isolation of a peptide for targeted drug delivery into human head and neck solid tumors," <u>Cancer Res 60</u> , pp. 6551-6556, December 2000.
XAMINER	DATE CONSIDERED
EXAMINER:	Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw

line through citation if not in conformance and not considered. Include any copy of this form with next